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ABSTRACT
Objectives To determine whether whole-body MRI
deﬁnes clinically relevant subgroups within polymyalgia
rheumatica (PMR) including glucocorticoid
responsiveness.
Methods 22 patients with PMR and 16 with rheumatoid
arthritis (RA), untreated and diagnosed by consultant
rheumatologists, underwent whole-body, multiple-joint
MRI, scored by two experts. Patients with PMR reported
whether they felt ‘back to normal’ on glucocorticoid
therapy and were followed for a median of 2 years.
Results All patients with PMR were deemed to respond
to glucocorticoids clinically. A characteristic pattern of
symmetrical, extracapsular inﬂammation, adjacent to
greater trochanter, acetabulum, ischial tuberosity and/or
symphysis pubis, was observed in 14/22 of the PMR cases.
In PMR, this pattern was associated with complete
glucocorticoid response (p=0.01), higher pretreatment C-
reactive protein (CRP) and serum interleukin-6 (IL-6), and
better post-treatment fatigue and function. Only 1/14 in
the extracapsular group could stop glucocorticoids within
1 year, compared with 4/7 of the others. A score derived
from the ﬁve sites discriminating best between PMR and
RA correlated with IL-6 (p<0.002). IL-6 levels ≥16.8 pg/
mL had 86% sensitivity and 86% speciﬁcity for the
extracapsular MRI pattern.
Conclusions A subset of patients with rheumatologist-
diagnosed PMR had a characteristic, extracapsular pattern
of MRI inﬂammation, associated with elevated IL-6/CRP
and with complete patient-reported glucocorticoid
responsiveness.
INTRODUCTION
Polymyalgia rheumatica (PMR) is a clinically diag-
nosed cause of glucocorticoid-responsive pain and
stiffness at the shoulders and hips, with great variation
in the duration of glucocorticoid treatment
required.1 2 PreviousMRI and 18-ﬂuorodeoxyglucose
(FDG)-positron emission tomography (PET) studies
have suggested distinct extracapsular3 4 or capsular-
based5 inﬂammation in PMR. Elevated pretreatment
interleukin-6 (IL-6) levels (>10 pg/mL) with good
symptomatic response to 20 mg prednisone was asso-
ciated with requirement for >1 year of therapy.6
Given the superior resolution of MRI compared with
18-FDG-PET, we sought to determine an anatomical
explanation for these ﬁndings.
Rheumatologists have traditionally been concerned
not to miss rheumatoid arthritis (RA) in patients with
PMR, although the anti-citrullinated peptide
(anti-CCP) antibody test has made this easier.7 8 We
designed this study to identify patterns of inﬂamma-
tion on whole-body, multiple-joint, 3-Tesla MRI9 that
distinguished PMR from RA but during follow-up we
were struck by the prognostic heterogeneity within
the PMR group. Given a known association of
ultrasound-deﬁned inﬂammation with glucocorticoid
responsiveness in PMR,10 we hypothesised that an
extracapsular pattern of inﬂammation in PMR pre-
dicts glucocorticoid response.
METHODS
Ethical approval was obtained (09/H1307/98,
approved by Leeds West Research Ethics Committee
15.1.10; 05/Q1108.28, York Research Ethics
Committee). All patients gave written, informed
consent.
Cases
Twenty-two consecutive patients with untreated
PMR fulﬁlling Bird criteria11 were identiﬁed by
two rheumatologists. All had an elevation of at
least one acute-phase marker (C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR)
plasma viscosity (PV)), were negative for rheuma-
toid factor and anti-CCP antibody and were com-
menced on prednisolone 15 mg after their MRI
scan, increasing to 20 mg at 1-month follow-up if
clinically indicated.
Patients recorded pain/stiffness location using
mannequins, and graded symptom severity using
visual analogue scores (VAS) and Stanford Health
Assessment Questionnaire - Disability Index
(HAQ-DI).12 Patients were asked whether they felt
‘back to normal since taking steroids’, on a ﬁve-
point Likert scale from ‘strongly agree’ to ‘strongly
disagree’. ‘Strongly agree’ and ‘agree’ were classi-
ﬁed as ‘yes’, others ‘no’. Standardised glucocortic-
oid taper was adjusted to maintain symptom
control until glucocorticoid cessation.2 Median
follow-up was 2 years.
Imaging controls
To minimise MRI scorer bias, 16 control MRI
scans were chosen from patients with seropositive
or seronegative RA.
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MRI
Whole-body multiple-joint MRI was performed9 (see online
supplementary methods). Gadolinium was used except where
contraindicated. The four non-contrast MRI image ﬁles were
evaluated (by DM, SLM and EF) to determine presence/
absence of extracapsular PMR pattern as previously described.3
All 34 whole-body, multiple-joint, contrast-enhanced MRI
image ﬁles were anonymised. Axial images were systematically
scored in ImageJ in the following order: spine, shoulders, hips,
hands, knees, feet. Each deﬁned site was semiquantitatively
consensus scored by the two experts (DM and EF), scoring 0,
1, 2 or 3, for no inﬂammation, mild, moderate or severe
inﬂammation respectively (ﬁgure 1). Each MRI was also classi-
ﬁed as ‘extracapsular pattern’ or ‘non-extracapsular pattern’.
The anonymisation code was not broken until the MRI scoring
datasheet (including overall classiﬁcation) had been locked
down.
IL-6 measurement
IL-6 was measured by ELISA (IL-6 Quantikine, R+D Systems)
using serum taken from consenting patients before MRI.
Analysis
We tested the hypothesis that an extracapsular pattern of disease
was associated with glucocorticoid responsiveness. Statistical
analyses were performed in SPSS V.21 (IBM).
RESULTS
Demographics and disease characteristics
At screening, all 22 patients with PMR fulﬁlled Bird criteria11
and (retrospectively) the provisional ACR/EULAR classiﬁcation
criteria,8 including elevation of at least one acute-phase marker;
in two PMR cases, however, acute-phase markers normalised by
the time the MRI scan was done. At follow-up, PMR was con-
ﬁrmed as the most likely diagnosis. All 22 patients were
recorded by the treating rheumatologist as responding to pred-
nisolone; in three cases an increase in dose was required for
complete response. No alternative explanation for patients’
musculoskeletal symptoms was found.
Training set (non-contrast) MRIs in PMR
Extracapsular inﬂammation3 was seen in 2/4 non-contrast MRI
scans of patients with PMR. Oedema was seen around the
Figure 1 Exemplar images of semiquantitative scoring system.
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greater trochanter in both, and of subdeltoid bursa, glenohum-
eral joint and below the symphysis pubis in one. There was no
difference between the patients with PMR who did and did not
receive contrast (see online supplementary table S2).
Gadolinium-enhanced whole-body multiple-joint MRI
The same extracapsular pattern was seen on contrast MRI as
with non-contrast MRI. Inﬂammation around the shoulders was
seen in both PMR and RA; PMR additionally featured pelvic
inﬂammation especially adjacent to greater trochanter and
ischial tuberosity (see online supplementary ﬁgure S1) and peri-
acetabular anterolateral to the rim of the acetabulum, without
involving the synovial hip joint and extending superiorly from
the anterior hip capsule, medial to gluteus minimus and lateral
to the iliac bone, not typical for iliopectinal (iliopsoas) bursitis
(see online supplementary ﬁgure S1). We additionally observed
inﬂammation inferior to the symphysis pubis (see online supple-
mentary ﬁgure S1). Bone oedema was absent. 14/22 of the
patients with PMR and 1/16 of the patients with RA were classi-
ﬁed as ‘extracapsular pattern’ (p<0.001). Results of semiquanti-
tative scoring (ﬁgure 1) are shown in ﬁgure 2.
Clinical associations of extracapsular pattern
Prior to glucocorticoid therapy, according to the rheumatologists’
assessments, the extracapsular group and the non-extracapsular
group appeared to have the same clinical syndrome of PMR with
no difference in the PMR-AS activity score.13 The non-
extracapsular group was all women, and had a lower CRP and
IL-6 (table 1). Males had a higher MRI inﬂammation score
(p=0.046) and a lower stiffness VAS (p=0.037), non-signiﬁcant
after Bonferroni correction (data not shown). 9/13 of those
scoring 2 or 3 at ischial tuberosity indicated buttock pain on
pain/stiffness mannequins, compared with 0/5 of the remainder
(sensitivity 69%, speciﬁcity 100%) (see online supplementary
ﬁgure S3).
Where questionnaire data were available from ﬁrst follow-up
(not done in three because of time constraints), 11/13 of those
with characteristic ‘extracapsular pattern’ of MRI inﬂammation,
and 1/6 of the remainder, stated that they felt ‘back to normal’
since taking steroids (p=0.01). This was reﬂected in better
patient-reported function (HAQ-DI) and fatigue VAS (table 1)
but no difference in post-treatment pain or stiffness VAS
between patients with and without the extracapsular pattern
(data not shown). The remaining three patients were later asked
whether they had felt ‘back to normal’ in the ﬁrst month after
taking steroids; therefore, 12/14 of all the patients with PMR an
extracapsular pattern felt ‘back to normal’, compared with 1/8
of those without an extracapsular pattern (p=0.001). Those
with an extracapsular pattern were less likely to be able to stop
glucocorticoid therapy within the ﬁrst year.
Figure 2 Results of blinded scoring of gadolinium-enhanced MRI scans. Prosthetic joints are treated as missing data (cells left blank). GC, glucocorticoid.
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The two patients with PMR extracapsular pattern who were
not complete glucocorticoid responders by self-report (ﬁgure 2)
had the highest IL-6 and CRP, and both required escalation of
prednisolone dose for full response. Another patient with extra-
capsular pattern later developed biopsy-proven giant cell
arteritis.
Association of IL-6 with MRI inﬂammation
The top ﬁve MRI features (mean of left and right) were summed
to provide a composite score. This was signiﬁcantly associated
with IL-6 (p<0.001) (see online supplementary ﬁgure S2) but
not with CRP (p=0.055). The most discriminatory IL-6 cut-off
for the extracapsular pattern was ≥16.8 pg/mL (sensitivity 86%,
speciﬁcity 86%).
DISCUSSION
All our patients were diagnosed with PMR by rheumatologists;
we sought to determine whether this could be further stratiﬁed
based on the pattern and extent of inﬂammation on whole-body
MRI. We identiﬁed a subset, with characteristic, extracapsular
pattern of inﬂammation on MRI that was more likely to feel
‘back to normal’ after glucocorticoids. MRI allowed good reso-
lution of pelvic inﬂammation. In addition, despite having more
males (male gender in PMR generally predicts shorter gluco-
corticoid duration14), our ‘extracapsular’ group was also more
likely to require glucocorticoid treatment for >1 year. IL-6 cor-
related with pelvic MRI inﬂammation; a cut-off of ≥16.8 pg/mL
IL-6 had 86% sensitivity and 86% speciﬁcity for the extracapsu-
lar pattern. Our data support an extra-articular model of the
primary inﬂammatory change in PMR.3 A recent report
describes focal 18-FDG-PET uptake anterior to the hip joint in
PMR15 similar to our ‘periacetabular’ pattern.
Strengths of this study include the standardised assessments
and the blinded MRI scoring. PMR diagnoses were all made by
a consultant rheumatologist, and all patients were treated as
PMR without any alternative diagnosis supervening.
The limitations of this study were its descriptive and explora-
tory nature, small numbers, slightly younger age of the RA
group, and the subjectivity inherent in clinical diagnosis of PMR
even following diagnostic guidelines.8 16 We hypothesise the
‘non-extracapsular’ patients with PMR may be a pathogeneti-
cally heterogeneous group, analogous to ‘autoantibody-negative
RA’. Whether they ought to be labelled PMR is a philosophical
question beyond the scope of this investigation.
This novel, pathoanatomical description of the clinical spec-
trum of PMR adds weight to the idea of PMR as a clinically het-
erogeneous disorder.1 MRI may help to identify a more
homogeneous subset, with potential value for deﬁning eligibility
for early clinical trials of targeted therapies. Our data suggest
that in the specialist setting CRP and IL-6 may be more
Table 1 Description of features of patients with polymyalgia rheumatica (PMR) with and without characteristic extracapsular pattern of
inflammation
Extracapsular pattern (n=14) Non-extracapsular pattern (n=8) p Value
Demographics
Age, median (range) 75 (55, 85) 78 (70, 84) 0.22
Male, n (%) 8 (57%) 0 (0%) 0.02
Acute-phase markers
ESR, median (range), mm/h 46 (9, 119) 38 (4, 81) 0.63
CRP, median (range), mg/L 36 (5, 118) 5.25 (5, 76) 0.03
PV, median (range), mPa s 1.93 (1.78, 2.12) 1.81 (1.57, 2.04) 0.36
IL-6, median (range), pg/mL 25.8 (0.3, 87.6) 6.0 (0.2, 131.5)* 0.04
Composite disease activity scores
PMR-AS (median, IQR) 78.6 (53.8, 103.0) 70.2 (34.4, 106.1) 0.73
Pretreatment patient-reported outcomes
Pain VAS (median, IQR) 7.7 (5.0, 8.1) 7.9 (4.3, 8.7) 0.63
Stiffness VAS (median, IQR) 6.3 (4.5, 8.0) 8.2 (5.2, 8.9) 0.29
Fatigue VAS (median, IQR) 7.1 (5.2, 7.6) 8.4 (7.0, 9.7) 0.03
HAQ-DI (median, IQR) 1.25 (1.09, 1.50) 1.56 (1.28, 2.09) 0.07
Assessment of glucocorticoid responsiveness at first follow-up
‘I feel back to normal since taking steroids’. n (%) 11/13 (85%) 1/6 (17%) 0.01
‘I feel [or felt] back to normal since taking steroids’. n (%) 12/14 (86%) 1/8 (13%) 0.001
Fatigue VAS at follow-up (median, IQR) 1.3 (0.2, 3.8) 7.1 (3.6, 9.8) 0.02
HAQ-DI at follow-up (median, IQR) 0 (0, 0.625) 1.0 (0.76, 2.07) 0.003
Prognosis
Stopped glucocorticoids permanently after <1 year† 1/14 4/7 0.03
Relapse-free† 7/14 2/8 1.00
Relapsed when on 5 mg or more† 3/14 3/7 0.35
Required initial dose increase >15 mg 2/14 1/8 1.00
The PMR-AS is the PMR Activity Score as described by Bird and Leeb. Either Mann–Whitney U test or Fisher’s exact test was used for non-normally distributed values; unpaired t test for
normally distributed variables. All tests were two-tailed. Apart from glucocorticoid responsiveness (the a priori hypothesis), p values should be interpreted in the light of multiple testing.
Bonferroni correction for all the variables reported here (likely over-stringent because of strong correlation between ESR/CRP/PV/IL-6 and between patient-reported VAS scores) would
require a threshold of 0.05/19, or p<0.0026.
*Excludes one patient who did not have IL-6 measured.
†Excludes one patient who was lost to follow-up at 4 months.
CRP, C-reactive protein; IL-6, interleukin-6; PV, plasma viscosity; VAS, visual analogue score.
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prognostically useful tests than ESR or PV. An MRI might be
useful in cases of diagnostic doubt. The diagnostic importance
of glucocorticoid responsiveness is still debated in PMR8 17
especially since the best way to measure response remains
unclear: the limitations of previously proposed disease activity
scores, including the physician global assessment and the
PMR-AS, have been well-discussed elsewhere.10 Although most
disease activity scores focus on pain and stiffness, we identiﬁed
residual fatigue and functional impairment after glucocorticoid
treatment in our non-extracapsular group; this is of interest
since fatigue18 and disability19 have been identiﬁed from recent
qualitative studies as being important to patients. We found that
MRI yielded additional valuable information to the clinical
assessment, particularly in the pelvic region where an extracap-
sular pattern was clearly seen in a distinct subset of patients.
Further research is required to determine the clinical utility of
MRI, symptom location (eg, buttock pain) or CRP/IL-6 as diag-
nostic, prognostic or treatment stratiﬁcation features in PMR.
Twitter Follow Sarah Mackie at @Sarah_L_Mackie
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